Sun Pharma posts Q1 profit on strong US sales

Tags: Companies
Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market, the United States.

April-June net profit was 13.91 billion rupees ($227.73 million), compared with a net loss of 12.76 billion rupees a year earlier. The prior-year period included a 25.17 billion rupee provision for settlement of a patent infringement litigation.

Analysts on average had expected a profit of 12.85 billion rupees, according to data compiled by Thomson Reuters.

Net sales rose 12 percent to 39.36 billion rupees, while sales in the United States, from where the company makes more than half its revenue, advanced 7 percent.

Sun Pharma is in the process of gaining regulatory approvals for its $3.2 billion acquisition of loss-making rival Ranbaxy Laboratories Ltd from Japan's Daiichi Sankyo Ltd and expects to close the deal by December.

The company has got approvals for the deal from anti-competition authorities in all applicable markets excluding India and the United States, Sun Pharma said in a statement late on Tuesday.

EDITORIAL OF THE DAY

  • CAG's observations on auction of coal blocks must be investigated by CVC

    Coal has an intrinsic relationship with fire.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Urs Schoettli

Look, who's blowing his own Trump(et)

Traditionally, major political events in the United States are followed ...

Zehra Naqvi

Deliciously desi

What’s the best way to spend a chilled-out weekend all ...

Bubbles Sabharwal

Good or bad, say thanks to the universe

It is true, life is richer than fiction. If we ...